Partnership to explore ‘transformational’ personalised cancer treatment

The treatments they develop with Isogenica will be tested on a ‘virtual patient’ in a lab, created from samples of a patient’s tumour cells and immune system.

The research team will test its new therapies on a virtual patient, which will be created using samples from a patient’s tumour and immune system (Lynne Cameron/PA)

Cancer patients could benefit from personalised treatment which experts have called “transformational”.

The University of Leicester has entered into a partnership with biotechnology company Isogenica to develop new immunotherapies.